23 January 2026 : Clinical Research
Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status
Mehmet Salim Demir
ABCDEFG 1*, Gözde Ağdaş BCFG 1
DOI: 10.12659/MSM.951548
Med Sci Monit 2026; 32:e951548
Figure 2 Kaplan-Meier overall survival curves by neoadjuvant chemotherapy regimen.Kaplan-Meier curves depicting overall survival by neoadjuvant chemotherapy regimen. Survival probabilities are shown for patients treated with dose-dense Adriamycin and Cyclophosphamide followed by taxane, trastuzumab, and pertuzumab (ddAC-THP) and for those treated with docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP). Tick marks indicate censored observations. A trend toward improved survival in the TCHP group is observed, although the difference was marginal in log-rank testing.